Diabetes market scale will continue to grow and antidiabetic drugs will be upgraded soon

[market analysis of chinapharma.com] according to relevant reports, the 2018 edition of the national essential drug catalogue will be published in the near future It is reported that on the basis of covering the main clinical diseases, the adjustment focuses on cancer, pediatrics, chronic diseases and other diseases 187 kinds of Chinese and Western medicines with clear effectiveness and safety and significant cost-benefit ratio are transferred in After the adjustment, the total varieties of the basic medicine catalogue will be expanded to 685 Among them, chronic medicine is one of the focuses It is understood that diabetes drugs are the focus of attention in chronic disease drugs According to relevant statistics, the market size of diabetes will continue to maintain a steady growth trend According to the data, in 2017, there were 120 million patients with type 2 diabetes in China, 52.3% of whom were not diagnosed; there were 435 million patients with type 2 diabetes in the world, with an undiagnosed rate of 45.8% It is estimated that by 2045, the number of diabetic patients will reach 629 million Due to the need for life-long medication, the market for diabetes drugs is huge According to statistics, in 2017, the global market for diabetes drugs reached 68.9 billion US dollars, and the market for diabetes drugs in China reached 51.2 billion yuan With the aging of population and the change of life style, diabetes has become an epidemic disease from rare disease Diabetes is a chronic disease, the pathogenesis is that the pancreas can not produce enough insulin or the pancreas can not use its insulin correctly Diabetic complications can lead to serious consequences such as myocardial infarction, cerebral hemorrhage, blindness, renal failure and lower limb amputation, which is one of the main risk factors affecting human life It is understood that although many pharmaceutical companies continue to improve and upgrade insulin, oral hypoglycemic drugs, GLP-1 / DPP-4 / sglt-2 target drugs to achieve better efficacy, there are still some unmet clinical needs due to the large number of patients, course differences, individual differences and other factors At present, there are many new targets of diabetes drugs in the world in the research and development process GK, GPR40, gpr119, AMPK and other targets are all temporarily unavailable products, and the basic progress is in phase 1 or phase 2 clinical China is a country with a large number of diabetics in the world, so it is very important to strengthen the research and development of diabetes drugs With the continuous improvement of the medical level, the continuous improvement of the diagnosis and treatment rate of diabetes in China promotes the continuous expansion of the domestic diabetes market It is reported that many pharmaceutical companies are carrying out bioequivalence test on healthy human body of caglejing tablets in drug imitation According to media reports, more than 20 domestic enterprises have obtained the Chinese clinical trial license of dagliejing In terms of new drug development, the development progress of gliclazin in domestic enterprises is also relatively fast, such as Hengrui's henggliclazin, which started phase III clinical trials in June last year In addition, jiaglijing of Shandong xuanzhu, rongglijing of dongyangyao, aigglijing of Shanghai Ellis and tagglijing of Tianjin Pharmaceutical Research Institute have all applied for clinical trials According to the industry, with the R & D and market layout capabilities of the latecomers' advantages, the share pattern of China's drug market will continue to be reconstructed rapidly The incidence rate of diabetes in China has risen rapidly, and the number of people suffering from diabetes has reached 114 million The market of the hypoglycemic drugs has received more and more attention So how to make related drugs not easy to cause hypoglycemia risk and effectively reduce the risk of complications? Pharmaceutical companies have been working hard It is reported that on May 25, Sansheng pharmaceutical announced that the weekly preparation of glucagon like peptide-1 receptor agonist (glp-1ra) "baidayang" (exenatide microspheres for injection) was officially launched This is a once-a-week antidiabetic drug approved for marketing in China Glp-1ra has now become a major driving force for the growth of antidiabetic drugs in the world At present, many domestic enterprises have been deployed From the perspective of the industry, the market upgrading of antidiabetic drugs is imminent According to the industry, with the rapid entry of imported glp-1ra into the domestic market, the competition will be white hot in three to five years According to the estimation of relevant organizations, by 2020, the sales volume of antidiabetic drugs in China will reach 50 billion yuan, and the market scale of glp-1ra will reach 2.5 billion yuan.